On December 6, 2017 Geron Corporation (Nasdaq:GERN) reported that the company’s analyst and investor meeting to discuss imetelstat clinical data will take place in New York, N.Y., on Tuesday, December 19, 2017 (Press release, Geron, DEC 6, 2017, View Source;p=RssLanding&cat=news&id=2321341 [SID1234522399]). The presentation will begin at 8:30 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Azra Raza, M.D., Professor of Medicine and Director of the Myelodysplastic Syndromes (MDS) Center at New York-Presbyterian/Columbia University Medical Center in New York City, will present data from Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of the telomerase inhibitor imetelstat in patients with lower risk MDS being conducted by Janssen Research & Development, LLC. These data have been accepted as a poster presentation at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition.
A live audio webcast of the presentation will be available through the Investors section of Geron’s website (www.geron.com) under Events. Following the live presentation, the webcast will be archived and available for replay for a period of 30 days.
To attend the meeting in person, please send an email to Gitanjali Jain Ogawa at The Trout Group ([email protected]) for further information.